2834 – Page 169 – China Stock Advice

SVA [SINOVAC BIOTECH] SC 13G: (Original Filing)

[Joint Filing Agreement SAIF Partners IV L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. SAIF IV GP, L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP,] [CUSIP No. P8696W104 Page 2 of 9 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands 5]

By info| 2016-03-24T02:34:35+00:00 November 15th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, SVA|0 Comments

SVA [SINOVAC BIOTECH] SC 13G: Joint Filing Agreement SAIF Partners IV L.P. Andrew

[Joint Filing Agreement SAIF Partners IV L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. SAIF IV GP, L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP,] [CUSIP No. P8696W104 Page 2 of 9 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands 5]

By info| 2016-03-24T02:36:15+00:00 November 15th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, SVA|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number PART I.FINANCIAL INFORMATION Item 1. Financial Statements 4nsolidated Balance Sheets of September 30, 2010 (unaudited) and December 31, 2009 4nsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months and Nine Months Ended September 30, 2010 and 2009 (unaudited)] [CERTIFICATE OF AMENDMENT AND CERTIFICATE OF CHANGE v202562_ex3-1.htm 3 EX-3.1] [CERTIFICATION I, Weibing Lu, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Michael H. Lan, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v202562_ex32-1.htm 37 EX-32.1] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) v202562_ex32-2.htm 38 EX-32.2]

By info| 2016-02-05T03:55:47+00:00 November 15th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number PART I.FINANCIAL

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number PART I.FINANCIAL INFORMATION Item 1. Financial Statements 4nsolidated Balance Sheets of September 30, 2010 (unaudited) and December 31, 2009 4nsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months and Nine Months Ended September 30, 2010 and 2009 (unaudited)] [CERTIFICATE OF AMENDMENT AND CERTIFICATE OF CHANGE v202562_ex3-1.htm 3 EX-3.1] [CERTIFICATION I, Weibing Lu, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Michael H. Lan, certify that: 1.I have reviewed this Quarterly 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v202562_ex32-1.htm 37 EX-32.1] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) v202562_ex32-2.htm 38 EX-32.2]

By info| 2016-02-05T03:56:37+00:00 November 15th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, REPORTS THIRD QUARTER REVENUEREASE OF 29.7% TO $20.2 MILLION XIANYANG, China, November 15, 2010 (Xinhua-PRNewswire-FirstCall) , - Q3 2010 revenuereased 29.7% to $20.2 million - Q3 2010 Non-GAAPjusted netomereased 11.9% to $3.5 million with Non-GAAPjusted EPS of $0.13 -sh andsh equivalents totaled $16.6 million at September 30]

By info| 2016-02-07T16:39:34+00:00 November 15th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2010-11-15, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, REPORTS THIRD QUARTER REVENUEREASE OF 29.7%

[BIOSTAR PHARMACEUTICALS, REPORTS THIRD QUARTER REVENUEREASE OF 29.7% TO $20.2 MILLION XIANYANG, China, November 15, 2010 (Xinhua-PRNewswire-FirstCall) , - Q3 2010 revenuereased 29.7% to $20.2 million - Q3 2010 Non-GAAPjusted netomereased 11.9% to $3.5 million with Non-GAAPjusted EPS of $0.13 -sh andsh equivalents totaled $16.6 million at September 30]

By info| 2016-02-07T16:40:09+00:00 November 15th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2010-11-15, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G: (Original Filing)

[securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be (Continued on the Following Pages) 1. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Kylin Fund LP 2. 3. 4. Delaware]

By info| 2016-04-02T18:55:56+00:00 November 15th, 2010|Categories: Chinese Stocks, SEC Original, WX|Tags: 0001403132, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, WX|0 Comments

WX [WuXi PharmaTech (Cayman)] SC 13G: securities, and for any subsequent amendment containing information

[securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be (Continued on the Following Pages) 1. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Kylin Fund LP 2. 3. 4. Delaware]

By info| 2016-04-02T18:56:54+00:00 November 15th, 2010|Categories: Chinese Stocks, Webplus ver, WX|Tags: 0001403132, 2010-11-15, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, WX|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x September 30, 2010

[FORM 10-Q (Mark One) x September 30, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.2 5 ex32-2.htm]

By info| 2016-03-03T13:47:17+00:00 November 12th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2010-11-12, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] DEFA14A: (Original Filing)

[SCHEDULE 14A INFORMATION þ o Check the appropriate box: o Preliminary Proxy Statement o 6(e)(2) ) o Definitive Proxy Statement þ Definitive Additional Materials o CHINA PHARMA HOLDINGS, INC. Payment of Filing Fee (Check the appropriate box): þ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1)]

By info| 2016-03-03T20:08:17+00:00 November 12th, 2010|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 2010-11-12, 2834, CPHI, DEFA14A, PHARMACEUTICAL PREPARATIONS|0 Comments